GSK plc vs Palo Alto Networks Inc — how do they compare? GSK plc trades at $51.15 (market cap $102.60B), while Palo Alto Networks Inc trades at $387.88 (market cap $312.80B). The key difference: Palo Alto Networks Inc is far larger — about 3× GSK plc's market cap, and GSK plc pays a 3.57% dividend while Palo Alto Networks Inc pays none. Which is the better fit depends on your goals.
| GSK | PANW | |
|---|---|---|
Market Cap | $102.60B | $312.80B |
Sector | Health | Technology |
52-Week High | $61.18 | $385.04 |
52-Week Low | $38.22 | $141.67 |
Enterprise Value | $123.04B | $311.76B |
Dividend Yield | 3.57% | — |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Palo Alto Networks (PANW) trades at $386.64, up 0.42% today, nearing its 52-week high with strong bullish technical signals. Recent earnings beats, including Q1 2026 EPS of $0.85 versus $0.793 expected, and robust revenue growth to $9.22B in 2025 highlight fundamental strength. Positive sentiment is driven by AI cybersecurity demand, as noted in recent news, though valuation ratios like P/E of 333.74 remain elevated.
Outlook is optimistic due to cybersecurity tailwinds and AI innovation, but risks include high valuation, integration costs from acquisitions, and regulatory scrutiny, such as China's cybersecurity review. Analyst consensus is strongly bullish with a $344.94 price target, suggesting potential downside from current levels amid growth execution risks.
Trailing returns across standard periods
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →